A sensitive Aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid

Journal of Neuroscience

Volumn 34, Issue 8, 2014, Pages 2884-2897

  Savage, Mary J ^a   Kalinina, Juliya ^a   Wolfe, Abigail ^a   Tugusheva, Katherine ^a   Korn, Rachel ^a   Cash Mason, Tanesha ^a   Maxwell, Jill W ^a   Hatcher, Nathan G ^a   Haugabook, Sharie J ^a   Wu, Guoxin ^a   Howell, Bonnie J ^a   Renger, John J ^a   Shughrue, Paul J ^a,b   McCampbell, Alexander ^a,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Prothena Biosciences Inc   (United States)

^c BIOGEN   (United States)

Author keywords

Abeta oligomer; Alzheimer

Indexed keywords

ABETA OLIGOMER; ALZHEIMER;

ADULT; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES; ANTIBODY SPECIFICITY; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SCATTERING, RADIATION;

EID: 84894073956     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1675-13.2014     Document Type: Article

References (71)

1. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H (2005) Globular amyloid beta-peptide oligomer-a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95:834-847. CrossRef Medline
2. Bateman RJ, Wen G, Morris JC, Holtzman DM (2007) Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68:666-669. CrossRef Medline
3. Benilova I, Karran E, De Strooper B (2012) The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15:349-357. CrossRef Medline
4. Bernstein SL, Wyttenbach T, Baumketner A, Shea JE, Bitan G, Teplow DB, Bowers MT (2005) Amyloid beta-protein: monomer structure and early aggregation states of Abeta42 and its Pro19 alloform. J Am Chem Soc 127:2075-2084. CrossRef Medline
5. Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T, Condron MM, Bitan G, Teplow DB, Shea JE, Ruotolo BT, Robinson CV, Bowers MT (2009) Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem 1:326-331. CrossRef Medline
6. Bitan G, Teplow DB (2004) Rapid photochemical cross-linking-a new tool for studies of metastable, amyloidogenic protein assemblies. Acc Chem Res 37:357-364. CrossRef Medline
7. Bitan G, Teplow DB (2005) Preparation of aggregate-free, low molecular weight amyloid-beta for assembly and toxicity assays. Methods Mol Biol 299:3-9. Medline
8. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB (2003) Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A 100: 330-335. CrossRef Medline
9. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, Andreasen N, Zetterberg H, Andreasson U, Blennow K (2010) Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis pii:986310. CrossRef Medline
10. Bruggink KA, Jongbloed W, Biemans EA, Veerhuis R, Claassen JA, Kuiperij HB, Verbeek MM (2013) Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Anal Biochem 433:112-120. CrossRef Medline
11. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliväli J, Lesné S, Ashe KH, Muchowski PJ, Mucke L (2007) Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282:23818-23828. CrossRef Medline
12. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL (2003) Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42:12749-12760. CrossRef Medline
13. Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML (2012) A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. Neuron 76:908-920. CrossRef Medline
14. DeMeyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67:949-956. CrossRef Medline
15. Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL (2013) Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 73:104-119. CrossRef Medline
16. Freir DB, Nicoll AJ, Klyubin I, Panico S, McDonald JM, Risse E, Asante EA, Farrow MA, Sessions RB, Saibil HR, Clarke AR, Rowan MJ, Walsh DM, Collinge J (2011) Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun 2:336. CrossRef Medline
17. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M (2010) High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24: 2716-2726. CrossRef Medline
18. Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, Levey AI, Krafft GA, Levy E, Checler F, Glabe C, Bilker WB, Abel T, Schmeidler J, Ehrlich ME (2010) Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol 68:220-230. CrossRef Medline
19. Gao CM, Yam AY, Wang X, Magdangal E, Salisbury C, Peretz D, Zuckermann RN, Connolly MD, Hansson O, Minthon L, Zetterberg H, Blennow K, Fedynyshyn JP, Allauzen S (2010) Abeta40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. PLo S One 5:e15725. CrossRef Medline
20. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 102:2273-2276. CrossRef Medline
21. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100:10417-10422. CrossRef Medline
22. Handoko M, Grant M, Kuskowski M, Zahs KR, Wallin A, Blennow K, Ashe KH (2013) Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol 70:594-599. CrossRef Medline
23. Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, Keller PM, Yeager M, Wang H, Shughrue P, Kinney G, Joyce JG (2006) Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 45:15157-15167. CrossRef Medline
24. Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT (2010) Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci 30:2442-2453. CrossRef Medline
25. Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT (2013) A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid. PLo S One 8:e67898. CrossRef Medline
26. Hölttä M, Hansson O, Andreasson U, Hertze J, Minthon L, Nägga K, Andreasen N, Zetterberg H, Blennow K (2013) Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. PLo S One 8:e66381. CrossRef Medline
27. Howlett DR, George AR, Owen DE, Ward RV, Markwell RE (1999) Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation. Biochem J 343:419-423. CrossRef Medline
28. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9:119-128. CrossRef Medline
29. Klein WL (2013) Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? J Alzheimers Dis 33:S49-65. Medline
30. Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D, Hou S, Kopeikina KJ, Frosch MP, Lee VM, Holtzman DM, Hyman BT, Spires-Jones TL (2012) Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 135:2155-2168. CrossRef Medline
31. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem271:4077-4081. CrossRef Medline
32. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24:10191-10200. CrossRef Medline
33. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95:6448-6453. CrossRef Medline
34. Lambert MP, Velasco PT, Viola KL, Klein WL (2009) Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. CNS Neurol Disord Drug Targets 8:65-81. CrossRef Medline
35. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352-357. CrossRef Medline
36. Le Vine H 3rd (2004) Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal Biochem 335:81-90. CrossRef Medline
37. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J (2004) Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/ Aβ40 ratio and total tau. Neurobiol Aging 25:273-281. CrossRef Medline
38. Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, Bibl M, Maler JM, Kornhuber J, Wiltfang J (2006) Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem 52:332-334. Medline
39. Li J, Llano DA, Ellis T, Le Blond D, Bhathena A, Jhee SS, Ereshefsky L, Lenz R, Waring JF (2012) Effect of human cerebrospinal fluid sampling frequency on amyloid-beta levels. Alzheimers Dement 8:295-303. CrossRef Medline
40. McDonald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM; Medical Research Council Cognitive Function and Ageing Study (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133:1328-1341. CrossRef Medline
41. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944. CrossRef Medline
42. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SS, Mount HT, Fraser PE, Westaway D, St George-Hyslop P (2006) Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12:801-808. CrossRef Medline
43. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860-866. CrossRef Medline
44. Mungas D (1991) In-office mental status testing: a practical guide. Geriatrics 46:54-58.
45. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Rönicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature 485:651-655. CrossRef Medline
46. O'Bryant SE, Humphreys JD, Smith GE, Ivnik RJ, Graff-Radford NR, Petersen RC, Lucas JA (2008) Detecting dementia with the mini-mental state examination in highly educated individuals. Arch Neurol 65:963-967. CrossRef Medline
47. Oe T, Ackermann BL, Inoue K, Berna MJ, Garner CO, Gelfanova V, Dean RA, Siemers ER, Holtzman DM, Farlow MR, Blair IA (2006) Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 20:3723-3735. CrossRef Medline
48. Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, Elmoualij B, Schraen S, Moreaud O, Gabelle A, Thouvenot E, Thomas-Anterion C, Touchon J, Krolak-Salmon P, Kovacs GG, Coudreuse A, Quadrio I, Lehmann S (2012) Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimers Dis 31:13-20. CrossRef Medline
49. Pica-Mendez AM, Tanen M, Dallob A, Tanaka W, Laterza OF (2010) Nonspecific binding of Abeta42 to polypropylene tubes and the effect of Tween-20. Clin Chim Acta 411:1833. CrossRef Medline
50. Pitschke M, Prior R, Haupt M, Riesner D (1998) Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 4:832-834. CrossRef Medline
51. Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H (2011) Novel aβ isoforms in Alzheimer's disease-their role in diagnosis and treatment. Curr Pharm Des 17:2594-2602. CrossRef Medline
52. Sancesario GM, Cencioni MT, Esposito Z, Borsellino G, Nuccetelli M, Martorana A, Battistini L, Sorge R, Spalletta G, Ferrazzoli D, Bernardi G, Bernardini S, Sancesario G (2012) The load of amyloid-β oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients. J Alzheimers Dis 31:865-878. CrossRef Medline
53. Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, Gregro AR, Hazuda D, Hochman JH, Holloway K, Jin L, Kahana J, Lai MT, Lineberger J, McGaughey G, Moore KP, Nantermet P, et al. (2009) First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther 328:131-140. CrossRef Medline
54. Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, Prvulovic D, Hansson O, Hampel H (2012) Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J Alzheimers Dis 29:171-176. CrossRef Medline
55. Sarsoza F, Saing T, Kayed R, Dahlin R, Dick M, Broadwater-Hollifield C, Mobley S, Lott I, Doran E, Gillen D, Anderson-Bergman C, Cribbs DH, Glabe C, Head E (2009) A fibril-specific, conformation-dependent antibody recognizes a subset of Ab plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol 118: 505-517. CrossRef Medline
56. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S (2008) Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med 14:1106-1111. CrossRef Medline
57. Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A 105:14052-14057. CrossRef Medline
58. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14:837-842. CrossRef Medline
59. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65:403-413. CrossRef Medline
60. Shughrue PJ, Acton PJ, Breese RS, Zhao WQ, Chen-Dodson E, Hepler RW, Wolfe AL, Matthews M, Heidecker GJ, Joyce JG, Villarreal SA, Kinney GG (2010) Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. Neurobiol Aging 31:189-202. CrossRef Medline
61. Slemmon JR, Meredith J, Guss V, Andreasson U, Andreasen N, Zetterberg H, Blennow K (2012) Measurement of Abeta1-42 in cerebrospinal fluid is influenced by matrix effects. J Neurochem 120:325-333. CrossRef Medline
62. Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM (2012) CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 78:709-719. CrossRef Medline
63. Todd J, Freese B, Lu A, Held D, Morey J, Livingston R, Goix P (2007) Ultrasensitive flow-based immunoassays using single-molecule counting. Clin Chem 53:1990-1995. CrossRef Medline
64. Tomic JL, Pensalfini A, Head E, Glabe CG (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35:352-358. CrossRef Medline
65. Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, Walsh DM, Selkoe DJ (2006) Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 60:668-676. CrossRef Medline
66. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, Ho JE, Fradley MG, Ghorbani A, Xanthakis V, Kempf T, Benjamin EJ, Levy D, Vasan RS, Januzzi JL (2012) Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 126: 1596-1604. CrossRef Medline
67. Wu G, Miller RA, Connolly B, Marcus J, Renger J, Savage MJ (2013) Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain. Neurodegener Dis. Advance online publication. doi:10.1159/000353634. CrossRef Medline
68. Xia W, Yang T, Shankar G, Smith I, Shen Y, Walsh DM, Selkoe DJ (2009) A specific enzyme-linked immunosorbent assay for measuring betaamyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66:190-199. CrossRef Medline
69. Yamamoto N, Matsubara E, Maeda S, Minagawa H, Takashima A, Maruyama W, Michikawa M, Yanagisawa K (2007) A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. J Biol Chem 282:2646-2655. Medline
70. Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ (2013) New ELISAs with high specificity for soluble oligomers of amyloid betaprotein detect natural Abeta oligomers in human brain but not CSF. Alzheimers Dement 9:99-112. CrossRef Medline
71. Zetzsche T, Rujescu D, Hardy J, Hampel H (2010) Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. Expert Rev Mol Diagn 10:667-690. CrossRef Medline